Medications for Hemophilia A
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hemophilia A.
Found 12 Approved Drugs for Hemophilia A
Hemlibra
Generic Name
Emicizumab
Hemlibra
Generic Name
Emicizumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: November 16, 2017
HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. HEMLIBRA is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. ( 1 )
Desmopressin Acetate
Brand Names
DDAVP, Nocdurna
Desmopressin Acetate
Brand Names
DDAVP, Nocdurna
Form: Injection, Spray, Tablet, Solution
Method of administration: Sublingual, Intravenous, Subcutaneous, Nasal, Oral
FDA approval date: May 01, 1984
Classification: Factor VIII Activator
Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention.
Sevenfact
Generic Name
VIIa
Sevenfact
Generic Name
VIIa
Form: Kit
Method of administration: Intravenous
FDA approval date: April 01, 2023
SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency. SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors ( 1 ). Limitation of Use: SEVENFACT is not indicated for treatment of congenital factor VII deficiency.
FEIBA
Generic Name
Anti-Inhibitor
FEIBA
Generic Name
Anti-Inhibitor
Form: Kit
FDA approval date: January 31, 1986
FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX. FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes. Perioperative management. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX. ( 1 )
Alhemo
Generic Name
Concizumab
Alhemo
Generic Name
Concizumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: February 19, 2025
Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors, hemophilia B (congenital factor IX deficiency) with FIX inhibitors Alhemo is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:, hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors, hemophilia B (congenital factor IX deficiency) with FIX inhibitors ( 1 )
Showing 1-5 of 12
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances